- All
- Announcements
- News
- Publications & Posters
Publications & Posters
11 September, 2023
Announcements
21 August, 2023
Hummingbird Bioscience, a data-driven precision biotherapeutics company discovering and developing transformative biologic medicines for hard-to-treat diseases, today announced an upcoming poster presentation at the IASLC 2023 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer (9-12 September 2023, Singapore). The poster will highlight the scientific rationale for combining anti-HER3 antibody HMBD-001 with EGFR inhibition and chemotherapy to improve treatment outcomes in squamous non-small cell lung cancer (sqNSCLC).
Announcements
27 July, 2023
Hummingbird Bioscience has initiated two clinical trials in Australia evaluating HMBD-001 in patients with squamous non-small cell lung cancer and patients with genetic aberrations in HER3 signaling. Hummingbird Bioscience has partnered with Omico to accelerate clinical development of HMBD-001, leveraging Omico’s PrOSPeCT initiative and network in Australia to recruit patients with gene signatures most likely to benefit from HMBD-001.
Publications & Posters
4 June, 2023
Announcements
29 May, 2023
VISTA blockade with HMBD-002 reprograms tumor associated macrophages and promotes cytotoxic T-cell response in preclinical studiesHMBD-002 in combination with anti-PD-1 treatment shows enhanced anti-tumor efficacy compared to monotherapy arms in preclinical studies HMBD-002 is currently being assessed in a Phase 1 study to determine the recommended Phase 2 dose as a monotherapy and in combination […]
Announcements
15 May, 2023
Hummingbird Bioscience, a data-driven precision biotherapeutics company discovering and developing transformative biologic medicines for hard-to-treat diseases, today announced it has entered into a clinical trial collaboration and supply agreement with Merck to evaluate HMBD-001 in combination with cetuximab in squamous non-small cell lung carcinoma
Announcements
8 May, 2023
Hummingbird Bioscience, a data-driven precision biotherapeutics company discovering and developing transformative biologic medicines for hard-to-treat diseases, today announced an upcoming poster presentation at IMMUNOLOGY2023™
Announcements
15 March, 2023
Hummingbird Bioscience, a data-driven precision biotherapeutics company discovering and developing transformative biologic medicines for hard-to-treat diseases, today announced two upcoming poster presentations at the American Association for Cancer Research (AACR) Meeting 2023 (April 14-19) in Orlando, Florida.
Announcements
6 March, 2023
Hummingbird Bioscience, a data-driven precision biotherapeutics company discovering and developing transformative biologic medicines for hard-to-treat diseases, and Cancer Research Horizons, the innovation arm of Cancer Research UK (CRUK), today announced that Hummingbird Bioscience has exercised its option to license in the first-in-human (FIH) clinical trial results of HMBD-001, a differentiated and potentially best-in-class HER3-targeting antibody.
Announcements
4 January, 2023
Synaffix B.V. (Synaffix), a biotechnology company focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs) with best-in-class therapeutic index, and Hummingbird Bioscience (Hummingbird Bio), a data-driven precision biotherapeutics company using its Rational Antibody Discovery (RAD) platform to discover and engineer antibodies against optimal yet elusive epitopes, thereby unlocking novel mechanisms of action, today announced that they entered into a licensing agreement that will enable Hummingbird Bio to develop a next generation ADC program using Synaffix technology.
Announcements
6 December, 2022
Collaboration to leverage Caris’ comprehensive (WES/WTS) molecular profiling technologies and large clinico-genomic database to elucidate biomarkers associated with response to HMBD-001, with the goal to increase the probability of clinical successIRVING, Texas and SINGAPORE, December 6, 2022 – Caris Life Sciences®(Caris), the leading molecular science and technology company actively developing and delivering innovative solutions to … Continue reading "Caris Life Sciences and Hummingbird Bioscience Enter Into Collaboration to Advance Clinical Development of Anti-HER3 Therapy"
Publications & Posters
16 November, 2022
Announcements
7 November, 2022
VISTA blockade with HMBD-002 reprograms tumor associated macrophages and promotes cytotoxic T-cell response in preclinical studiesHMBD-002 in combination with anti-PD-1 treatment shows enhanced anti-tumor efficacy compared to monotherapy arms in preclinical studies HMBD-002 is currently being assessed in a Phase 1 study to determine the recommended Phase 2 dose as a monotherapy and in combination […]
Announcements
1 November, 2022
San Francisco & Houston & Singapore, November 1, 2022 – Hummingbird Bioscience, a data-driven precision biotherapeutics company discovering and developing transformative biologic medicines for hard-to-treat diseases, today announced that Chief Financial Officer Josh House and Chief Development Officer Leah DiMascio will participate in one-on-one investor meetings at the Credit Suisse 31st Annual Global Healthcare Conference […]
News
23 September, 2022
Announcements
23 September, 2022
San Francisco & Houston & Singapore, September 23, 2022 – Hummingbird Bioscience, a data-driven precision biotherapeutics company discovering and developing transformative biologic medicines for hard-to-treat diseases, today announced the official opening of its office and research facilities at the Singapore Science Park. Deputy Prime Minister and Coordinating Minister for Economic Policies Heng Swee Keat officiated […]
Announcements
19 September, 2022
San Francisco & Houston & Singapore, September 19, 2022 – Hummingbird Bioscience, a data-driven precision biotherapeutics company discovering and developing transformative biologic medicines for hard-to-treat diseases, today announced that Jerome Boyd-Kirkup, Ph.D., Hummingbird Bioscience’s Chief Scientific Officer, will present at the 2nd Annual VISTA Symposium on September 23, 2022.“VISTA is a promising therapeutic target we […]
Announcements
8 September, 2022
– HMBD-001 is a proprietary anti-HER3 antibody in an ongoing Phase 1 trial targeting multiple solid tumors– HMBD-001 has the potential to fully block both ligand-dependent and -independent HER3 signalingSan Francisco & Houston & Singapore, September 8, 2022 – Hummingbird Bioscience, a data-driven precision biotherapeutics company discovering and developing transformative biologic medicines for hard-to-treat diseases, […]
Announcements
6 September, 2022
San Francisco & Houston & Singapore, September 6, 2022 – Hummingbird Bioscience, a data-driven precision biotherapeutics company discovering and developing transformative biologic medicines for hard-to-treat diseases, today announced that Chief Executive Officer Piers Ingram, Ph.D., and Chief Financial Officer Josh House will participate in one-on-one investor meetings at Morgan Stanley’s 20th Annual Global Healthcare Conference […]
Announcements
9 February, 2022
Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets in cancer and autoimmune disease, today announced the publication of preclinical data for HMBD-002, a novel anti-VISTA antibody therapeutic, in the Journal for ImmunoTherapy of Cancer, a peer-reviewed journal of the Society for Immunotherapy of Cancer.
Announcements
6 December, 2021
Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets in cancer and autoimmune disease, and Cancer Research UK, the world’s leading cancer charity, today announced that the first patient has been dosed in a Phase 1 clinical trial of HMBD-001 for the treatment of patients with advanced HER3-expressing solid malignancies (NCT05057013).
Announcements
29 November, 2021
Hummingbird Bioscience Holdings Limited, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets in cancer and autoimmune disease, today announced the appointment of Jan Møller Mikkelsen as Chairman of its Board of Directors.
Announcements
10 November, 2021
Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets, today announced a Trials in Progress poster presentation outlining the Phase 1 clinical trial design for HMBD-002, a unique anti-VISTA antibody developed using Hummingbird’s Rational Antibody Discovery platform to address VISTA-mediated suppression of anti-tumor immune responses, at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC). The meeting will be held in Washington, D.C. and virtually from November 10 to 14, 2021.
Announcements
25 October, 2021
Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets to improve treatment outcomes, today announced it has entered into a clinical trial collaboration agreement with Merck.
Announcements
7 October, 2021
Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets, today announced the presentation of pre-clinical data on novel biomarkers for HER3-driven cancers at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics 2021. The conference will take place from October 7 to 10, 2021.
Publications & Posters
7 October, 2021
Announcements
23 September, 2021
Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets, has opened its new office location at the Singapore Science Park. The new base strengthens its Singapore presence and complements its offices in the United States at Texas Medical Centre and South San Francisco.
Announcements
13 September, 2021
Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets, today announced that the U.S. Food and Drug Administration (FDA) has approved the initiation of a Phase 1 clinical trial of HMBD-002, Hummingbird’s anti-VISTA neutralizing antibody.
Announcements
1 September, 2021
Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets, today announced the appointment of Josh House as Chief Financial Officer, effective immediately.
Announcements
2 August, 2021
Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets, today announced that the UK Medicines and Healthcare Products Regulatory Agency (MHRA) has approved the clinical trial application (CTA) to initiate first-in-human phase 1 trial of HMBD-001 in patients with advanced cancers.
Announcements
26 July, 2021
Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets, today announced that internationally renowned scientist and medical oncologist, Dr. Thomas J Lynch, Jr, MD, has been appointed to its Board as a Non-Executive Director, effective immediately.
Announcements
12 July, 2021
Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets to produce major improvements in treatment outcomes, and The University of Texas MD Anderson Cancer Center today announced the launch of a multi-year strategic research collaboration to investigate and evaluate HMBD-002, Hummingbird’s VISTA antagonist antibody.
Announcements
15 June, 2021
Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets, today announced that its Chief Scientific Officer and co-founder, Dr Jerome Boyd-Kirkup, will be speaking at the 2021 virtual symposium “VISTA: A New Immune Checkpoint in Cancer, Autoimmunity and Beyond”, taking place on June 18, 2021.
Announcements
9 June, 2021
Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets, today announced a strategic partnership with Asian genomic sequencing and bioinformatics company Novogene Co., Ltd. (“Novogene”).
Announcements
31 May, 2021
Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets today announced that its abstract reporting pre-clinical results from its V-domain immunoglobulin suppressor of T cell activation (VISTA) antibody, HMBD-002, has been selected for publication at the American Society of Clinical Oncology (ASCO) Annual Meeting, to be held June 4-8, 2021.
News
27 May, 2021
Pharma Intelligence’s Insights speaks to Hummingbird CEO Piers Ingram following the Singapore-based company’s Series C financing round.
News
27 May, 2021
Hummingbird discusses our HER3 program and how we are tackling the challenges of therapeutics development.
News
27 May, 2021
Hummingbird discusses why cutting-edge digital tools and data-rich computational approaches play a powerful role in the development of precision biotherapeutics.
Announcements
18 May, 2021
Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets to improve treatment outcomes, today announced the close of its US$125 million Series C financing round.
Announcements
10 April, 2021
Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets to improve treatment outcomes, today announced that the company will be presenting pre-clinical data on its BCMA-TACI dual-specific T cell engager, HMBD-009, at the 2021 American Association for Cancer Research (AACR) Annual Meeting taking place 9-14 April.
Publications & Posters
10 April, 2021
News
24 February, 2021
Hummingbird discusses how systems biology and data science have advanced the understanding of disease, and how Hummingbird’s unique multidisciplinary approach unites the power of these two fields to create revolutionary therapies.
News
17 February, 2021
Hummingbird speaks to DealStreetAsia about Hummingbird’s overall drug development moving into clinical trials this year and why setting milestones drive future investments.
News
28 January, 2021
Hummingbird Bioscience has been recognized with the Most Promising Innovation title at Singapore’s SG:D Techblazer Awards 2020, the nation’s highest accolade for tech innovation.
News
12 January, 2021
The Business Times lists Hummingbird Bioscience as one of the Top 10 Startups to watch in Singapore in 2021.
News
17 December, 2020
Hummingbird Bioscience is collaborating with Tempus to advance HMBD-001, a differentiated anti-HER3 neutralizing antibody developed using Hummingbird’s Rational Antibody Discovery platform, into clinical trials in HER3-driven cancers, including those that harbor neuregulin 1 (NRG1) fusions. Read the full story on BioWorld.
Announcements
14 December, 2020
Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing revolutionary therapies for hard-to-drug targets, today announced a collaboration with Tempus, a leader in artificial intelligence and precision medicine, to drive the development of Hummingbird’s lead clinical program, HMBD-001, as it advances into clinical trials in HER3-driven cancers, including those that harbor neuregulin 1 (NRG1) fusions.
News
17 November, 2020
A new Covid-19 treatment could become available in Singapore and beyond by early 2021 as homegrown biotech company Hummingbird Bioscience joins major names in making steps to combat the coronavirus.
Publications & Posters
27 October, 2020
SARS-CoV-2-neutralizing antibodies are promising therapeutics for COVID-19. However, little is known about the mechanisms of action of these antibodies.
News
24 August, 2020
Global business has faced unprecedented challenges over the past 12 months, particularly in 2020.
News
23 August, 2020
Global business has faced unprecedented challenges over the past 12 months, particularly in 2020.
News
25 July, 2020
The Parker Institute for Cancer Immunotherapy (PICI) announced today that John Connolly, Ph.D., has been named chief scientific officer (CSO). In this role, Connolly.
Announcements
10 May, 2020
Hummingbird Bioscience enters a collaboration with Omico. Under this collaboration, Omico will support planning for and provide patient referrals to Hummingbird Bioscience’s biomarker-driven trials for HMBD-001, a potentially best-in-class HER3-targeting antibody.
Announcements
5 December, 2019
Hummingbird Bioscience, an innovative biotherapeutics company pioneering the discovery and development of new breakthrough precision antibody therapeutics for difficult-to-treat conditions, today announced that it has raised US$19 million in a Series B financing round.
Announcements
16 September, 2019
Hummingbird Bioscience, an innovative systems-biology enabled biotechnology company, has today announced a multi-target collaboration to co-discover novel antibody therapeutics with Amgen. This partnership brings together Hummingbird’s proprietary drug discovery platform with Amgen’s disease expertise and drug development capabilities.
Announcements
8 August, 2019
Cancer Research UK, the world’s leading cancer charity, and Hummingbird Bioscience, an innovative systems-biology enabled biotechnology company, have today (Thursday) announced a partnership to develop Hummingbird’s anti-HER3 antibody drug, HMBD-001, for the treatment of people with HER3 driven cancer.
Announcements
25 February, 2019
Hummingbird Bioscience announced today it has been awarded a product development grant totalling $13.1 million by the Cancer Prevention and Research Institute of Texas (CPRIT).
Announcements
18 February, 2019
Hummingbird Bioscience, a systems-biology enabled biotech company focused on the discovery and development of novel cancer therapeutics, today announced James P. Allison, Ph.D. and Padmanee Sharma, M.D., Ph.D., have joined its Scientific Advisory Board.
Announcements
9 November, 2018
Hummingbird Bioscience, a systems biology powered drug discovery and development company focused on novel cancer therapeutics, will present a poster “HMBD-002-V4: A novel anti-VISTA antibody that uniquely neutralizes VISTA activity and potently inhibits tumor growth by remodeling an immunosuppressive tumor microenvironment” at the Society for Immunotherapy of Cancer Annual Meeting taking place in Washington D.C. on November 9-11, 2018.
Announcements
5 November, 2018
Hummingbird Bioscience, a systems biology powered drug discovery and development company focused on novel cancer therapeutics, will present a poster “HMBD-002-V4: A novel anti-VISTA antibody that uniquely neutralizes VISTA activity and potently inhibits tumor growth by remodeling an immunosuppressive tumor microenvironment” at the Society for Immunotherapy of Cancer Annual Meeting taking place in Washington D.C. on November 9-11, 2018.
Announcements
10 April, 2018
Hummingbird Bioscience, a drug discovery and development company focused on novel cancer immuno-therapeutics, will present a poster “HMBD-002-V4, an Anti-VISTA Neutralizing Antibody, Displays Potent Anti-Tumor Efficacy in Combination with Anti-PD(L)1, Through Release of MDSC Mediated Immunosuppresion in the TME” at the American Association for Cancer Research Annual Meeting in Chicago taking place from 14-18 April, 2018.
Publications & Posters
7 December, 2017
Announcements
4 December, 2017
Announcements
3 May, 2017
Hummingbird is focused on applying advances in systems biology to rapidly develop antibodies into successful cancer therapeutics. The company will use the funds raised to advance its lead programs towards the clinic with plans to submit the first IND in 2018. The programs in question; HMBD-001 targeting a novel mechanism on HER3, and HMBD-002 targeting a novel epitope on VISTA, have already shown great promise in early animal studies.
